The bio-tools giant, Thermo Fisher Scientific, today reported modest increases in year over year revenue for Q3 2024.  Most of the gains were attributed to Specialty Diagnostics, and Analytical Instruments, while Life Sciences Solutions, dipped slightly. Laboratory Products and Pharmaceutical Services (largest sector) was essentially flat.  As the Bio-tools sector continues to work it way out of the year-long slump, Marc Casper, chairman, president and CEO of Thermo Fisher Scientific said, “We are pleased to deliver strong financial results in the third quarter, reflecting another quarter of sequential improvement in growth,”. Casper also reiterated optimism at hitting the revenue objectives for the full year.  – Source: Thermo Fisher Scientific